Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1 1

Status

Completed 9Terminated 3Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Multiple Myeloma 61Lymphoma, Follicular 16Recurrence 13Lymphoma, Non-Hodgkin 12Lymphoma, Mantle-Cell 12Lymphoma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, B-Cell, Marginal Zone 9Lymphoma, Large B-Cell, Diffuse 8Leukemia, Lymphocytic, Chronic, B-Cell 8Waldenstrom Macroglobulinemia 7Neoplasms 7Neoplasms, Plasma Cell 6Lymphoma, Large-Cell, Anaplastic 5Leukemia, Myeloid, Acute 5Immunoblastic Lymphadenopathy 5Lymphoma, T-Cell, Cutaneous 4Hodgkin Disease 4Carcinoma, Non-Small-Cell Lung 4Sezary Syndrome 3Prostatic Neoplasms 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Myelodysplastic Syndromes 3Mycosis Fungoides 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, B-Cell 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia, Erythroblastic, Acute 3Leukemia 3

Interventions

Rituximab 24Cyclophosphamide 14fludarabine 8Etoposide 6Vincristine 5Prednisone 5Doxorubicin 5fludarabine phosphate 4Carboplatin 4venetoclax 3obinutuzumab 3ibrutinib 3atezolizumab 3Whole-Body Irradiation 3Mycophenolic Acid 3Lenalidomide 3Ifosfamide 3Cytarabine 3Carmustine 3Bortezomib 3Bendamustine Hydrochloride 3ublituximab 2pembrolizumab 2pegfilgrastim 2ibritumomab tiuxetan 2Tiragolumab 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Melphalan 2Indium 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Lymphoma, B-Cell × Bortezomib × Clear all
NCT00413959 2018-09-19

VRCD

Oncology Specialists, S.C.

Phase 2 Terminated
12 enrolled 7 charts
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT01300793 2012-09-26

V-RICE

University of California, San Francisco

Phase 1 Terminated
6 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT00515138 2012-04-12

A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant

University of California, San Francisco

Phase EARLY_PHASE1 Terminated
7 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡